Spatial proteomics (PhenoCycler, PhenoImager) used to map immune cells in tumours; acquired by Quanterix in July 2025.
Akoya Biosciences, based in Marlborough, Massachusetts, and formerly listed as AKYA, makes spatial proteomics instruments, PhenoCycler and PhenoImager, used to map immune cells in tumours, and it became a wholly owned subsidiary of Quanterix on 8 July 2025. Its multiplex immunofluorescence runs at scale, and clinical partnerships aim at spatial signatures that predict immunotherapy response. OnCo links it to spatial biology instruments. Whether a spatial immune signature can be validated as a companion diagnostic for immunotherapy, which is the promise behind the whole sector, is the open question. The spatial biology instruments page carries the wider field.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Closed 8 July 2025 under an amended merger agreement; Quanterix's 10-Q gives a total fair value of consideration of 151.0 million dollars, including Quanterix shares, about 18.9 million dollars in cash and repayment of Akoya's debt | 2025 | $151M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Spatial biology instruments and the tag supporting.
Shares Spatial biology instruments and the tag supporting.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/